Craig-Hallum raised the firm’s price target on Indivior (INDV) to $41 from $34 and keeps a Buy rating on the shares. The firm cites the company’s Q3 massive beat, delivering revenue of $314M, beating Street estimates of $261.9M, with broad-based strength from both Sublocade and Suboxone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INDV:
- Indivior price target raised to $40 from $30 at Northland
- Indivior price target raised to $41 from $27 at Piper Sandler
- Indivior PLC Reports Q3 2025 Results and Optimizes Strategy
- Indivior’s Strong Q3 Performance and Growth Potential Drive Buy Rating
- Indivior price target raised to $35 from $28 at H.C. Wainwright